Skin / appearance research
GHK-Cu vs Acetyl octapeptide-3
Separate topical human data, mechanism and formulation; avoid treating all cosmetic peptides as interchangeable.
At a glance
GHK-Cu
Acetyl octapeptide-3
Human evidence
Human evidence is route-specific and mixed. A randomized venous-ulcer study of topical 0.4% copper-tripeptide cream found no superiority over vehicle, and a 13-person randomized post-CO2-laser study found no significant objective skin benefit, although subjective satisfaction favored treatment. Injectable/systemic evidence remains much weaker.
Human cosmetic studies of microneedle formulations containing acetyl octapeptide-3 report wrinkle/skin-quality improvements, but the studied products also contained other active ingredients.
Research focus
Skin, wound healing, collagen, hair/cosmetic research
Topical cosmetic wrinkle research
Regulatory status
Injectable GHK-Cu is not an FDA-approved therapeutic product; FDA highlights compounded-injection safety uncertainty.
Cosmetic ingredient rather than an approved injectable therapeutic.
Route / formulation
Topical cosmetic evidence cannot be automatically extrapolated to injected GHK-Cu.
Product-level effects from multi-active microneedle formulations cannot be attributed wholly to acetyl octapeptide-3.
No head-to-head clinical evidence identified Separate topical human data, mechanism and formulation; avoid treating all cosmetic peptides as interchangeable.